JP2024504164A - Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ - Google Patents

Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ Download PDF

Info

Publication number
JP2024504164A
JP2024504164A JP2023544489A JP2023544489A JP2024504164A JP 2024504164 A JP2024504164 A JP 2024504164A JP 2023544489 A JP2023544489 A JP 2023544489A JP 2023544489 A JP2023544489 A JP 2023544489A JP 2024504164 A JP2024504164 A JP 2024504164A
Authority
JP
Japan
Prior art keywords
cells
icd
codon
tmd
optimized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504164A5 (enExample
Inventor
レズヴァニ、ケイティ
シュポール、エリザベス
バサール、ラフェット
アチャリヤ、スニル
ウプレティ、ナディマ
コスタ、ダビド マリン
エンスリー、エミリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2024504164A publication Critical patent/JP2024504164A/ja
Publication of JP2024504164A5 publication Critical patent/JP2024504164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023544489A 2021-01-25 2022-01-24 Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ Pending JP2024504164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163141016P 2021-01-25 2021-01-25
US63/141,016 2021-01-25
US202163270414P 2021-10-21 2021-10-21
US63/270,414 2021-10-21
PCT/US2022/013458 WO2022159791A1 (en) 2021-01-25 2022-01-24 Cd27-extracellular domain car to target cd70-positive tumors

Publications (2)

Publication Number Publication Date
JP2024504164A true JP2024504164A (ja) 2024-01-30
JP2024504164A5 JP2024504164A5 (enExample) 2025-01-29

Family

ID=82549264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544489A Pending JP2024504164A (ja) 2021-01-25 2022-01-24 Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ

Country Status (9)

Country Link
US (1) US20250281612A1 (enExample)
EP (1) EP4281483A4 (enExample)
JP (1) JP2024504164A (enExample)
KR (1) KR20230136184A (enExample)
AU (1) AU2022210461A1 (enExample)
CA (1) CA3209110A1 (enExample)
IL (1) IL304635A (enExample)
MX (1) MX2023008676A (enExample)
WO (1) WO2022159791A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251290A1 (en) * 2023-06-09 2024-12-12 Suzhou Cure Genetics Biosciences Co., Limited Engineered immune cells and uses thereof
WO2025029351A1 (en) * 2023-07-28 2025-02-06 Adicet Therapeutics, Inc. Multispecific chimeric antigen receptor (car)-t cells directed to cd70 and methods of use thereof
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504148A (ja) * 2010-10-27 2014-02-20 ベイラー カレッジ オブ メディスン Ｔ細胞をｃｄ７０陽性悪性腫瘍に仕向けるためのキメラなｃｄ２７受容体
JP2018505139A (ja) * 2014-12-08 2018-02-22 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019119036A1 (en) * 2017-12-19 2019-06-27 Benitec Biopharma Limited Cd70 deficient cells, and methods and reagents for producing same
CN109880802B (zh) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
WO2020259541A1 (zh) * 2019-06-25 2020-12-30 浙江康佰裕生物科技有限公司 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用
WO2022129216A1 (en) * 2020-12-15 2022-06-23 Universiteit Antwerpen Cell-based therapeutics targeting cd70

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504148A (ja) * 2010-10-27 2014-02-20 ベイラー カレッジ オブ メディスン Ｔ細胞をｃｄ７０陽性悪性腫瘍に仕向けるためのキメラなｃｄ２７受容体
JP2018505139A (ja) * 2014-12-08 2018-02-22 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAHER M. ET AL.: "Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells", BLOOD, vol. vol.137(5), JPN6025051894, 4 February 2021 (2021-02-04), pages 624 - 636, ISSN: 0005756100 *
KANG S. ET AL.: "The Advances and Challenges of NK Cell-Based Cancer Immunotherapy", CURR ONCOL., vol. vol.28(2), JPN6025051892, 26 February 2021 (2021-02-26), pages 1077 - 1093, ISSN: 0005756098 *
LIU E. ET AL.: "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence a", LEUKEMIA, vol. vol.32(2), JPN6025051893, 2018, pages 520 - 531, ISSN: 0005756099 *

Also Published As

Publication number Publication date
WO2022159791A1 (en) 2022-07-28
CA3209110A1 (en) 2022-07-28
EP4281483A1 (en) 2023-11-29
IL304635A (en) 2023-09-01
MX2023008676A (es) 2023-08-02
AU2022210461A9 (en) 2024-05-09
US20250281612A1 (en) 2025-09-11
KR20230136184A (ko) 2023-09-26
AU2022210461A1 (en) 2023-08-24
EP4281483A4 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US20240252539A1 (en) Chimeric antigen receptor to target hla-g-positive cancers
US20240325444A1 (en) Chimeric antigen receptor to target trop-2-positive cancers
JP2024504164A (ja) Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ
EP4065691A1 (en) Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers
JP7690211B2 (ja) Ｃｄ７０陽性腫瘍を標的化するようにナチュラルキラー細胞を操作する方法
JP2024537176A (ja) ナチュラルキラー細胞及びその使用方法
US20230040477A1 (en) T-cell death associated gene 8 (tdag8) modulation to enhance cellular cancer therapies
US20240382593A1 (en) Antibody loaded immune cells and methods for use in cancer treatment
JP2023549674A (ja) 癌の処置用の免疫調節治療薬としての免疫細胞におけるｓｒｃ－３の標的化
CA3176258A1 (en) Cell immunotherapy for the treatment of cancer
JP2025503987A (ja) ペイロードを発現するように操作された腫瘍浸潤リンパ球
US20230285558A1 (en) Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
CN116964097A (zh) 靶向cd70阳性肿瘤的cd27胞外结构域car

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260311